CEO: Emily Stern, MD.

Visit Website

Ceretype Neuromedicine is a precision neuropsychiatry company transforming treatment development and patient care by integrating the most advanced understanding of neurologic and psychiatric biology with the latest in functional MRI (fMRI) methods and AI technologies. Ultimately, Ceretype aims to change the standard of care to first-time-right treatment with the use of clinical fMRI tools, to help large populations of patients. Psychiatric patients desperately need effective treatment solutions for their mental health challenges, without the risks and delays of a trial-and-error approach.